Licensing status

Publication and contact information

Drug platforms

Improving drug-like properties of protein therapeutics through peptide extensions that interact with the Fc fragment of IgG receptor transporter-a (FCGRT; FCRN)

Peptide extensions that promote the interaction of proteins with FCRN could improve the drug-like properties of protein therapeutics. Some protein therapeutics are conjugated to the Fc domain of IgG, which interacts with FCRN, to increase plasma half-life, but the large size of the resulting fusion protein can interfere with tissue penetration and biological activity. In a proof-of-principle experiment, short peptide sequences that compete with IgG for binding to FCRN were conjugated to the N-terminal and/or C-terminal ends of a fluorescent protein. In cell culture, the peptide-based fusion proteins were internalized and transcytosed across a cell monolayer, which is similar to what is seen with IgG fusions. Next steps include testing peptide-modified protein therapeutics in animal models.

SciBX 5(41); doi:10.1038/scibx.2012.1096
Published online Oct. 18, 2012

Patent application filed; available for licensing

Sockolosky, J.T. et al. Proc. Natl. Acad. Sci. USA; Sept. 18, 2012;
Contact: Francis C. Szoka, University of California, San Francisco, Calif.